“90后”董事离任！深圳知名药企公告

Group 1 - Shenzhen Xinlitai Pharmaceutical Co., Ltd. announced the resignation of director Shen Qing due to personal reasons, effective immediately, and he will not hold any position in the company thereafter [1] - Dr. Xu Wenjie, the head of the research institute, has been elected as the employee representative director, bringing 16 years of drug development experience and is a key inventor of the company's core patent [1] - Xinlitai focuses on the research and commercialization of cardiovascular drugs, medical devices, cephalosporin antibiotics, and orthopedic drugs since its establishment in 1998 and listing in 2009 [1] Group 2 - For the first three quarters of 2025, the company achieved a total operating revenue of 3.241 billion yuan, representing a year-on-year growth of 8.01%, and a net profit attributable to shareholders of 581 million yuan, with a year-on-year increase of 13.93% [2]